Tecentriq for small cell lung cancer – pro
Atezoluzumab was FDA approved on 9/6/2018 with carboplatin and etoposide for small cell lung cancer as first line based on the IMpower133, a double-blind study of PD-L1 inhibitor atezolizumab (Tecentriq, Genentech) among 403 treatment-naive patients with extensive-stage small cell lung cancer. assigned patients to carboplatin and etoposide with atezolizumab (n = 201) or with placebo (n = 202) for 21-day cycles during the induction phase. During the maintenance phase, patients received atezolizumab or placebo until unacceptable toxicities, disease progression according to RECIST v1.1, or no additional clinical benefit was observed.
Investigator-assessed PFS and OS in the intention-to-treat population served as co-primary endpoints.
Median follow-up was 13.9 months.
The results published simultaneously in The New England Journal of Medicine showed median OS was 12.3 months in the atezolizumab arm compared with 10.3 months in the placebo arm (HR for death = 0.7; 95% CI, 0.54-0.91).
Researchers reported median PFS of 5.2 months with atezolizumab vs. 4.3 months with placebo (HR for disease progression or death = 0.77; 95% CI, 0.62-0.96).
The safety profile for the combination appeared consistent with the known safety profiles of the individual medicines. The addition of frontline atezolizumab to carboplatin plus etoposide improved OS and PFS among patients with extensive-stage small cell lung cancer, according to results of a multinational, randomized, placebo-controlled phase 3 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer. IMpower133 is a double-blind study of PD-L1 inhibitor atezolizumab (Tecentriq, Genentech) among 403 treatment-naive patients with extensive-stage small cell lung.
The addition of frontline atezolizumab to carboplatin plus etoposide improved OS and PFS among patients with extensive-stage small cell lung cancer, according to results of a multinational, randomized, placebo-controlled phase 3 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer. IMpower133 is a double-blind study of PD-L1 inhibitor atezolizumab (Tecentriq, Genentech) among 403 treatment-naive patients with extensive-stage small cell lung.
Leora Horn, M.D., Aaron S. Mansfield, M.D., Aleksandra Szczęsna, M.D., Libor Havel, M.D., Maciej Krzakowski, M.D., Ph.D., Maximilian J. Hochmair, M.D., Florian Huemer, M.D., György Losonczy, M.D., Ph.D., Melissa L. Johnson, M.D., Makoto Nishio, M.D., Ph.D., Martin Reck, M.D., Tony Mok, M.D., et al., for the IMpower133 Study Group, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. NEJM September 25, 2018
Leora Horn, M.D., Aaron S. Mansfield, M.D., Aleksandra Szczęsna, M.D., Libor Havel, M.D., Maciej Krzakowski, M.D., Ph.D., Maximilian J. Hochmair, M.D., Florian Huemer, M.D., György Losonczy, M.D., Ph.D., Melissa L. Johnson, M.D., Makoto Nishio, M.D., Ph.D., Martin Reck, M.D., Tony Mok, M.D., et al., for the IMpower133 Study Group, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. NEJM September 25, 2018